

50. The method of claim 20, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

51. The method of claim 21, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

52. The method of claim 22, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

53. The method of claim 24, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

54. The method of claim 26, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

55. The composition of claim 40, wherein the composition further comprises an additional amino acid sequence or nucleic acid sequence that is not an *atonal*-associated nucleic acid sequence or amino acid sequence.

It is believed that a \$9.00 fee is due in connection with this paper; please charge the fee to our Deposit Account No. 06-2375 order 09906355. If any other fees are required, please charge them to the same account. A duplicate copy of this letter is enclosed for that purpose.

Respectfully submitted,



Melissa L. Sistrunk  
Registration No. 45,579

**Fulbright & Jaworski L.L.P.**  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
(713) 651-3735

Dated: 28 September 2001